(lp0
S'Catalyst Biosciences reports 4Q loss Yahoo Finance - Mar 8, 2017  _ Catalyst Biosciences Inc.  on Wednesday reported a loss of $3.7 million in its fourth quarter. The South San Francisco, California-based company said it had a loss of $4.68 per share.Catalyst Biosciences Reports Fourth Quarter and Full Year 2016 Financial ... - GlobeNewswire Catalyst Biosciences Inc - Receive News &amp; Ratings Daily - BBNS'
p1
aS'Catalyst Biosciences Announces Promotion of Andrew Hetherington to SVP of ... GlobeNewswire  - Feb 16, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 16, 2017  -- Catalyst Biosciences, Inc.,  a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that&nbsp;...'
p2
aS'Catalyst Biosciences Completes Merger With Targacept and Creates a Protease ... GlobeNewswire  - Aug 20, 2015 SOUTH SAN FRANCISCO, Calif., Aug. 20, 2015  -- Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions,&nbsp;...Targacept sale to Catalyst is complete - Winston-Salem Journal'
p3
aS'Catalyst Biosciences Inc. MarketWatch - Dec 14, 2013 Catalyst Biosciences Inc. NASDAQ: CBIO. GO. Set Alerts &middot; Find a Broker &middot; Join TD Ameritrade &middot; Market Index &middot; Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.'
p4
aS'Catalyst Biosciences Inc. CBIO  Wall Street Journal - Aug 7, 2011 News Catalyst Biosciences Inc.CBIO. Significant News Only. 03/08/17; Press Release. Catalyst Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update.'
p5
aS'Catalyst Biosciences ending future research, eliminating half of workforce Winston-Salem Journal - Sep 7, 2016 The biopharmaceutical company that holds the remaining cash of defunct Targacept Inc. said Wednesday it is foregoing future research to focus on two drugs in its development pipeline.'
p6
aS'Catalyst Biosciences  Enters Agreement with Wyeth StreetInsider.com - Dec 14, 2016 On December 8, 2016, Catalyst Biosciences, Inc.  entered into a definitive agreement  with Wyeth LLC, a wholly-owned subsidiary of Pfizer Inc.  following the June 1, 2015 termination of the research and license&nbsp;...'
p7
aS"Stock Update : Here's Why Catalyst Biosciences Inc Is ... Smarter Analyst - Dec 15, 2016 On December 8, 2016, Catalyst Biosciences Inc  entered into a definitive agreement with Wyeth LLC, a wholly-owned subsidiary of Pfizer Inc. following the June 1, 2015 termination of the research and license agreement that was entered into&nbsp;...Revenue Estimates Analysis: Catalyst Biosciences, Inc.  - News OracleUnusual 11 Mid-Day Movers 12/15:    Higher;  (PIR ... - StreetInsider.com"
p8
aS'BRIEF-Catalyst Biosciences secures all rights to manufacturing process for ... Reuters - Dec 19, 2016 BEIJING, Feb 10 U.S. President Donald Trump told Chinese President Xi Jinping his administration would respect the &quot;one China&quot; policy, during a telephone call between the leaders, the Financial Times reported, citing two people familiar with the call.'
p9
aS'Catalyst Biosciences Names Andrew Hetherington as Vice President of ... GlobeNewswire  - Sep 28, 2015 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2015  -- Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions,&nbsp;...'
p10
a.